BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol 2014; 20(31): 10802-10812 [PMID: 25152583 DOI: 10.3748/wjg.v20.i31.10802] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Guerard A, Ayav A, Busby H, Lafitte M, Rousseau H, Laurent V. Early liver metastases in resectable periampullary cancer: Incidence and risk factors. European Journal of Radiology 2017;93:265-72. [DOI: 10.1016/j.ejrad.2017.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Jiang B, Zhou L, Lu J, Wang Y, Liu C, Liang Z, Zhou W, You L, Guo J. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2021;36:507-15. [PMID: 32875609 DOI: 10.1111/jgh.15244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cheng CS, Liu W, Zhou L, Tang W, Zhong A, Meng Z, Chen L, Chen Z. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. Biomed Res Int 2019;2019:1356264. [PMID: 31886169 DOI: 10.1155/2019/1356264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F, Takano S, Fukasawa M, Sato T, Enomoto N. Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol 2016;7:982-8. [PMID: 28078122 DOI: 10.21037/jgo.2016.06.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
5 Kaltenmeier C, Nassour I, Hoehn RS, Khan S, Althans A, Geller DA, Paniccia A, Zureikat A, Tohme S. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. J Gastrointest Surg 2020. [PMID: 33269460 DOI: 10.1007/s11605-020-04870-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ji F, Kang Q, Wang L, Liu L, Ke Y, Zhu Y, Zhang N, Xiong S, Li Y, Zou H. Prognostic significance of the neutrophil-to-lymphocyte ratio with distal cholangiocarcinoma patients. Medicine (Baltimore) 2020;99:e22827. [PMID: 33120809 DOI: 10.1097/MD.0000000000022827] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wen C, Deng X, Ren D, Song X, Chen H, Wang J, Jin J, Cheng D, Xu Z, Zhang J, Xie J, Qi W, Gu J, Peng C, Chen D, Chen S, Shen B, Zhan Q. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Cancer Med 2020;9:7626-36. [PMID: 32862515 DOI: 10.1002/cam4.3425] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Chong JU, Kim SH, Hwang HK, Kang CM, Lee WJ. Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer. Oncotarget 2017;8:110830-6. [PMID: 29340019 DOI: 10.18632/oncotarget.22734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Rasmussen LS, Yilmaz MK, Falkmer UG, Poulsen LØ, Bøgsted M, Christensen HS, Bojesen SE, Jensen BV, Chen IM, Johansen AZ, Hansen CP, Hasselby JP, Holländer N, Nielsen SE, Andersen F, Bjerregaard JK, Pfeiffer P, Johansen JS. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer: Analysis of the prognostic effect of serum vitamin D on pancreatic cancer: Several confounders. Eur J Cancer 2021;158:248-50. [PMID: 34642028 DOI: 10.1016/j.ejca.2021.09.009] [Reference Citation Analysis]
10 Subramani R, Gonzalez E, Arumugam A, Nandy S, Gonzalez V, Medel J, Camacho F, Ortega A, Bonkoungou S, Narayan M, Dwivedi Ak, Lakshmanaswamy R. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci Rep. 2016;6:19819. [PMID: 26804739 DOI: 10.1038/srep19819] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 11.5] [Reference Citation Analysis]
11 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Kim SH, Woo YS, Lee KH, Lee JK, Lee KT, Park JK, Kang SH, Kim JW, Park JK, Park S. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. Gastrointestinal Endoscopy 2018;88:926-34. [DOI: 10.1016/j.gie.2018.06.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
13 Gu J, Xu W, Peng C, Zhu Y, Wang D, Wang X, Li Y, Wei G, Zhang Z, Zhong Y, Zhao S, Shi M, Cheng D, Ying X, Jin J, Chen H. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. J Cell Biochem 2019. [PMID: 30756419 DOI: 10.1002/jcb.28457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Meng Z, Cao M, Zhang Y, Liu Z, Wu S, Wu H. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. BMC Gastroenterol 2019;19:59. [PMID: 31014264 DOI: 10.1186/s12876-019-0975-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Dai WF, Beca J, Guo H, Isaranawatchai W, Schwartz D, Naipaul R, Arias J, Qiao Y, Gavura S, Redmond-Misner R, Ismail Z, Barbera L, Chan K. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Cancer Med 2020;9:215-24. [PMID: 31736256 DOI: 10.1002/cam4.2704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, van de Velde CJ, Vahrmeijer AL, Bonsing BA, Mieog JS, Swijnenburg RJ. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106:1055-1065. [PMID: 30883699 DOI: 10.1002/bjs.11115] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 21.0] [Reference Citation Analysis]
17 Wang Q, Ni Q, Wang X, Zhu H, Wang Z, Huang J. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival. Med Oncol 2015;32:372. [PMID: 25428385 DOI: 10.1007/s12032-014-0372-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
18 Hong S, Song KB, Hwang DW, Lee JH, Lee W, Jun E, Kwon J, Park Y, Park SY, Kim N, Shin D, Kim H, Sung M, Ryu Y, Kim SC. Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma. World J Gastrointest Surg 2021; 13(11): 1423-1435 [DOI: 10.4240/wjgs.v13.i11.1423] [Reference Citation Analysis]
19 Goldstein D, Von Hoff DD, Chiorean EG, Reni M, Tabernero J, Ramanathan RK, Botteman M, Aly A, Margunato-Debay S, Lu B, Louis CU, McGovern D, Lee CK. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Pancreas 2020;49:744-50. [PMID: 32541630 DOI: 10.1097/MPA.0000000000001563] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Armando F, Fayyad A, Arms S, Barthel Y, Schaudien D, Rohn K, Gambini M, Lombardo MS, Beineke A, Baumgärtner W, Puff C. Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma. Int J Mol Sci 2021;22:3578. [PMID: 33808256 DOI: 10.3390/ijms22073578] [Reference Citation Analysis]
21 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
23 Sheikh M, Masoudi S, Bakhshandeh R, Moayyedkazemi A, Zamani F, Nikfam S, Mansouri M, Shishavan NG, Nikeghbalian S, Brennan P, Malekzadeh R, Pourshams A. Survival features, prognostic factors, and determinants of diagnosis and treatment among Iranian patients with pancreatic cancer, a prospective study. PLoS One 2020;15:e0243511. [PMID: 33275621 DOI: 10.1371/journal.pone.0243511] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yin L, Xiao L, Gao Y, Wang G, Gao H, Peng Y, Zhu X, Wei J, Miao Y, Jiang K, Lu Z. Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer. Med Oncol 2020;37:46. [PMID: 32277286 DOI: 10.1007/s12032-020-01370-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Dell'Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, Russano M, Cursano MC, Napolitano A, Zeppola T, Vincenzi B, Tonini G, Santini D. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020;11:924-41. [PMID: 32206189 DOI: 10.18632/oncotarget.27518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
26 Wainberg ZA, Feeney K, Lee MA, Muñoz A, Gracián AC, Lonardi S, Ryoo BY, Hung A, Lin Y, Bendell J, Hecht JR. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens. BMC Cancer 2020;20:633. [PMID: 32641104 DOI: 10.1186/s12885-020-07110-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
28 Wang W, Park C, Oh E, Sung Y, Lee J, Park K, Kang H. Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta , Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway. J Nat Prod 2019;82:3357-65. [DOI: 10.1021/acs.jnatprod.9b00646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ouyang H, Ma W, Liu F, Yue Z, Fang M, Quan M, Pan Z. Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Pancreatology 2017;17:773-81. [PMID: 28734721 DOI: 10.1016/j.pan.2017.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Liu J, Song N, Huang Y, Chen Y. Irisin inhibits pancreatic cancer cell growth via the AMPK-mTOR pathway. Sci Rep 2018;8:15247. [PMID: 30323244 DOI: 10.1038/s41598-018-33229-w] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
31 De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 2016;16:709. [PMID: 27590845 DOI: 10.1186/s12885-016-2671-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
32 Ikuta S, Aihara T, Yamanaka N. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma. Asia Pac J Clin Oncol 2019;15:e109-14. [PMID: 30632282 DOI: 10.1111/ajco.13123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
33 Sala Elarre P, Oyaga-Iriarte E, Yu KH, Baudin V, Arbea Moreno L, Carranza O, Chopitea Ortega A, Ponz-Sarvise M, Mejías Sosa LD, Rotellar Sastre F, Larrea Leoz B, Iragorri Barberena Y, Subtil Iñigo JC, Benito Boíllos A, Pardo F, Rodríguez Rodríguez J. Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. Cancers (Basel) 2019;11:E606. [PMID: 31052270 DOI: 10.3390/cancers11050606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
34 Felix K, Hinz U, Dobiasch S, Hackert T, Bergmann F, Neumüller M, Gronowitz S, Bergqvist M, Strobel O. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas 2018;47:72-9. [PMID: 29189449 DOI: 10.1097/MPA.0000000000000966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 2016;115:789-96. [PMID: 27599039 DOI: 10.1038/bjc.2016.271] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
36 Baig Z, Abu-Omar N, Khan R, Verdiales C, Frehlick R, Shaw J, Wu FX, Luo Y. Prognosticating Outcome in Pancreatic Head Cancer With the use of a Machine Learning Algorithm. Technol Cancer Res Treat 2021;20:15330338211050767. [PMID: 34738844 DOI: 10.1177/15330338211050767] [Reference Citation Analysis]
37 Choi MH, Lee YJ, Yoon SB, Choi JI, Jung SE, Rha SE. MRI of pancreatic ductal adenocarcinoma: texture analysis of T2-weighted images for predicting long-term outcome. Abdom Radiol (NY) 2019;44:122-30. [PMID: 29980829 DOI: 10.1007/s00261-018-1681-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
38 Hashimoto Y, Ishida M, Ryota H, Yamamoto T, Kosaka H, Hirooka S, Yamaki S, Kotsuka M, Matsui Y, Yanagimoto H, Tsuta K, Satoi S. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Pancreatology 2019;19:443-8. [DOI: 10.1016/j.pan.2019.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
39 Feng Z, Chen P, Li K, Lou J, Wu Y, Li T, Peng C. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Front Mol Biosci 2021;8:650264. [PMID: 34631790 DOI: 10.3389/fmolb.2021.650264] [Reference Citation Analysis]
40 Huang X, Zhi X, Gao Y, Ta N, Jiang H, Zheng J. LncRNAs in pancreatic cancer. Oncotarget. 2016;7:57379-57390. [PMID: 27429196 DOI: 10.18632/oncotarget.10545] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
41 Park JK, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH. Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy. Cancers (Basel) 2021;13:2791. [PMID: 34205170 DOI: 10.3390/cancers13112791] [Reference Citation Analysis]
42 Kato T, Ban D, Tateishi U, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. J Hepatobiliary Pancreat Sci 2020;27:114-23. [PMID: 31702106 DOI: 10.1002/jhbp.700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chen YG, Pan HH, Dai MS, Lin C, Lu CS, Su SL, Chang PY, Huang TC, Chen JH, Wu YY, Chen YC, Ho CL. Impact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive Jaundices. Medicine (Baltimore) 2015;94:e1298. [PMID: 26252308 DOI: 10.1097/MD.0000000000001298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
44 Arnachellum RP, Cariou M, Nousbaum JB, Jezequel J, Le Reste JY, Robaszkiewicz M. Pancreatic Adenocarcinoma in the Finistère Area, France, Between 2002 and 2011 (1002 Cases): Population Characteristics, Treatment and Survival. Pancreas 2016;45:953-60. [PMID: 26765965 DOI: 10.1097/MPA.0000000000000594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Naqvi AAT, Hasan GM, Hassan MI. Investigating the role of transcription factors of pancreas development in pancreatic cancer. Pancreatology 2018;18:184-90. [DOI: 10.1016/j.pan.2017.12.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
46 Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X, Goel A. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Ann Surg 2020. [PMID: 32398486 DOI: 10.1097/SLA.0000000000003945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Li X, Li S, Liu L, Hong J, Zhao T, Gao C. Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. J Cancer 2020;11:9-15. [PMID: 31892968 DOI: 10.7150/jca.33767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Zhu Y, Tian J, Peng X, Wang X, Yang N, Ying P, Wang H, Li B, Li Y, Zhang M, Cai Y, Lu Z, Niu S, Li Y, Zhong R, Chang J, Miao X. A genetic variant conferred high expression of CAV2 promotes pancreatic cancer progression and associates with poor prognosis. Eur J Cancer 2021;151:94-105. [PMID: 33975060 DOI: 10.1016/j.ejca.2021.04.008] [Reference Citation Analysis]
49 Si W, Liu X, Wei R, Zhang Y, Zhao Y, Cui L, Hong T. MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity. Cell Death Dis 2019;10:206. [PMID: 30814496 DOI: 10.1038/s41419-019-1424-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
50 Lee CT, Hu JX, Liu CM. Exploring prior diseases associated with pancreatic cancer. Curr Probl Cancer 2021;:100707. [PMID: 33589273 DOI: 10.1016/j.currproblcancer.2021.100707] [Reference Citation Analysis]
51 Zhao H, Wang Q, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J. Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer. Pancreas 2016;45:204-10. [PMID: 26418905 DOI: 10.1097/MPA.0000000000000453] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
52 Li S, Zhang G, Li X, Li X, Chen X, Xu Y, Ren H. Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Pharmacogenomics 2021;22:657-67. [PMID: 34120460 DOI: 10.2217/pgs-2020-0183] [Reference Citation Analysis]
53 Xing H, Hao Z, Zhu W, Sun D, Ding J, Zhang H, Liu Y, Huo L. Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics. EJNMMI Res. 2021;11:19. [PMID: 33630176 DOI: 10.1186/s13550-021-00760-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Martinho RP, Bao Q, Markovic S, Preise D, Sasson K, Agemy L, Scherz A, Frydman L. Identification of variable stages in murine pancreatic tumors by a multiparametric approach employing hyperpolarized 13 C MRSI, 1 H diffusivity and 1 H T1 MRI. NMR Biomed 2021;34:e4446. [PMID: 33219722 DOI: 10.1002/nbm.4446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Wennerblom J, Saksena P, Jönsson C, Thune A. Lymph node 8a as a prognostic marker for poorer prognosis in pancreatic and periampullary carcinoma. Scand J Gastroenterol 2018;53:225-30. [PMID: 29262727 DOI: 10.1080/00365521.2017.1417474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Chakraborty J, Langdon-Embry L, Cunanan KM, Escalon JG, Allen PJ, Lowery MA, O'Reilly EM, Gönen M, Do RG, Simpson AL. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. PLoS One 2017;12:e0188022. [PMID: 29216209 DOI: 10.1371/journal.pone.0188022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
57 Alhasan SF, Haugk B, Ogle LF, Beale GS, Long A, Burt AD, Tiniakos D, Televantou D, Coxon F, Newell DR, Charnley R, Reeves HL. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. Br J Cancer 2016;115:797-804. [PMID: 27560551 DOI: 10.1038/bjc.2016.264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
58 Chen YJ, Hou MC, Yang TC, Lee PC, Chao Y, Li CP, Huang YH, Lee FY. The clinical significance of esophagogastric varices in patients with advanced pancreatic cancer. J Chin Med Assoc 2021;84:917-22. [PMID: 34613941 DOI: 10.1097/JCMA.0000000000000609] [Reference Citation Analysis]
59 Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother 2021;:1-10. [PMID: 34919493 DOI: 10.1080/21645515.2021.2003645] [Reference Citation Analysis]
60 MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers (Basel) 2021;13:5501. [PMID: 34771664 DOI: 10.3390/cancers13215501] [Reference Citation Analysis]
61 Sperti C, Friziero A, Serafini S, Bissoli S, Ponzoni A, Grego A, Grego E, Moletta L. Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer. J Clin Med 2020;9:E2169. [PMID: 32659933 DOI: 10.3390/jcm9072169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Herting CJ, Karpovsky I, Lesinski GB. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer Metastasis Rev 2021;40:675-89. [PMID: 34591240 DOI: 10.1007/s10555-021-09988-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Kim HJ, Park MS, Lee JY, Han K, Chung YE, Choi JY, Kim MJ, Kang CM. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. Cancer Res Treat 2019;51:24-33. [PMID: 29397657 DOI: 10.4143/crt.2017.404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
64 Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. Gastroenterol Res Pract 2018;2018:2373868. [PMID: 29983708 DOI: 10.1155/2018/2373868] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
65 Parmar A, Chaves-Porras J, Saluja R, Perry K, Rahmadian AP, Santos SD, Ko YJ, Berry S, Doherty M, Chan KKW. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2020;145:102817. [PMID: 31955005 DOI: 10.1016/j.critrevonc.2019.102817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
66 Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther 2018;35:1564-77. [PMID: 30209750 DOI: 10.1007/s12325-018-0784-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
67 Khachfe HH, Habib JR, Nassour I, Al Harthi S, Jamali FR. Borderline Resectable and Locally Advanced Pancreatic Cancers: A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions. Pancreas 2021;50:1243-9. [PMID: 34860806 DOI: 10.1097/MPA.0000000000001924] [Reference Citation Analysis]
68 Jiang B, Zhou L, Lu J, Wang Y, Liu C, Zhou W, Guo J. Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer. Scand J Gastroenterol 2021;56:59-67. [PMID: 33284659 DOI: 10.1080/00365521.2020.1853806] [Reference Citation Analysis]